Stangel M - Search Results

1

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE^NMO Study.

Hümmert MW, Schöppe LM, Bellmann-Strobl J, Siebert N, Paul F, Duchow A, Pellkofer H, Kümpfel T, Havla J, Jarius S, Wildemann B, Berthele A, Bergh FT, Pawlitzki M, Klotz L, Kleiter I, Stangel M, Gingele S, Weber MS, Faiss JH, Pul R, Walter A, Zettl UK, Senel M, Stellmann JP, Häußler V, Hellwig K, Ayzenberg I, Aktas O, Ringelstein M, Schreiber-Katz O, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Among authors: stangel m. Neurology. 2022 Mar 15;98(11):e1184-e1196. doi: 10.1212/WNL.0000000000200052. Epub 2022 Jan 26. Neurology. 2022. PMID: 35082170 Free PMC article.

2

Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro.

Zettl UK, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. Zettl UK, et al. Among authors: stangel m. Cell Immunol. 1997 May 25;178(1):1-8. doi: 10.1006/cimm.1997.1113. Cell Immunol. 1997. PMID: 9184692

3

Oxides and apoptosis in inflammatory myopathies.

Stangel M, Mix E, Zettl UK, Gold R. Stangel M, et al. Microsc Res Tech. 2001 Nov 15;55(4):249-58. doi: 10.1002/jemt.1174. Microsc Res Tech. 2001. PMID: 11748863 Review.

4

Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation.

Pul R, Nguyen D, Schmitz U, Marx P, Stangel M. Pul R, et al. Among authors: stangel m. Clin Neuropharmacol. 2002 Sep-Oct;25(5):254-9. doi: 10.1097/00002826-200209000-00005. Clin Neuropharmacol. 2002. PMID: 12410056

5

[Chemokine--possible new options for the treatment of multiple sclerosis].

Trebst C, Ransohoff RM, Windhagen A, Stangel M. Trebst C, et al. Among authors: stangel m. Nervenarzt. 2003 Oct;74(10):850-7. doi: 10.1007/s00115-003-1571-9. Nervenarzt. 2003. PMID: 14551688 Review. German.

6

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M. Trebst C, et al. Among authors: stangel m. Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. doi: 10.1055/s-2004-830119. Fortschr Neurol Psychiatr. 2005. PMID: 16052440 Review. German.

7

[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ].

Trebst C, Wiendl H, Stangel M. Trebst C, et al. Among authors: stangel m. Nervenarzt. 2006 Feb;77(2):158, 160-2, 164. doi: 10.1007/s00115-005-1994-6. Nervenarzt. 2006. PMID: 16160810 Review. German.

8

Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.

Trebst C, Stangel M. Trebst C, et al. Among authors: stangel m. Curr Pharm Des. 2006;12(2):241-9. doi: 10.2174/138161206775193118. Curr Pharm Des. 2006. PMID: 16454740 Review.

9

Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach.

Stangel M, Gold R, Gass A, Haas J, Jung S, Elias W, Zettl UK. Stangel M, et al. J Neurol. 2006 Feb;253 Suppl 1:I32-6. doi: 10.1007/s00415-006-1108-9. J Neurol. 2006. PMID: 16477485 No abstract available.

10

Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Stangel M, Trebst C. Stangel M, et al. Curr Neurol Neurosci Rep. 2006 May;6(3):229-35. doi: 10.1007/s11910-006-0010-2. Curr Neurol Neurosci Rep. 2006. PMID: 16635432 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

365 results

Search Page

Filters